Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug 2;14(8):16076-86.
doi: 10.3390/ijms140816076.

Acetylcholinesterase reactivators (HI-6, obidoxime, trimedoxime, K027, K075, K127, K203, K282): structural evaluation of human serum albumin binding and absorption kinetics

Filip Zemek  1 , Jana Karasova Zdarova, Vendula Sepsova, Kamil Kuca
Affiliations

Acetylcholinesterase reactivators (HI-6, obidoxime, trimedoxime, K027, K075, K127, K203, K282): structural evaluation of human serum albumin binding and absorption kinetics

Filip Zemek et al. Int J Mol Sci. .

Abstract

Acetylcholinesterase (AChE) reactivators (oximes) are compounds predominantly targeting the active site of the enzyme. Toxic effects of organophosphates nerve agents (OPNAs) are primarily related to their covalent binding to AChE and butyrylcholinesterase (BChE), critical detoxification enzymes in the blood and in the central nervous system (CNS). After exposure to OPNAs, accumulation of acetylcholine (ACh) overstimulates receptors and blocks neuromuscular junction transmission resulting in CNS toxicity. Current efforts at treatments for OPNA exposure are focused on non-quaternary reactivators, monoisonitrosoacetone oximes (MINA), and diacylmonoxime reactivators (DAM). However, so far only quaternary oximes have been approved for use in cases of OPNA intoxication. Five acetylcholinesterase reactivator candidates (K027, K075, K127, K203, K282) are presented here, together with pharmacokinetic data (plasma concentration, human serum albumin binding potency). Pharmacokinetic curves based on intramuscular application of the tested compounds are given, with binding information and an evaluation of structural relationships. Human Serum Albumin (HSA) binding studies have not yet been performed on any acetylcholinesterase reactivators, and correlations between structure, concentration curves and binding are vital for further development. HSA bindings of the tested compounds were 1% (HI-6), 7% (obidoxime), 6% (trimedoxime), and 5%, 10%, 4%, 15%, and 12% for K027, K075, K127, K203, and K282, respectively.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of the standard Acetylcholinesterase (AChE) reactivators used.
Figure 2
Figure 2
Novel AChE reactivators tested in this study.
Figure 3
Figure 3
Pharmacokinetic curves of the standards.
Figure 4
Figure 4
Pharmacokinetic curves of the tested novel oximes.
See this image and copyright information in PMC

References

    1. Singh S.S. Preclinical pharmacokinetics: An approach towards safer and efficacious drugs. Curr. Drug Metab. 2006;7:165–182. - PubMed
    1. Lipinski C.A., Lombardo F., Dominy S.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery. Adv. Drug Deliv. Rev. 1997;23:3–25. - PubMed
    1. Walters W.P. Going further than Lipinski’s rule in drug design. Expert Opin. Drug Discov. 2012;7:99–107. - PubMed
    1. Sudlow G., Birkett D.J., Wade D.N. The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol. 1975;11:824–832. - PubMed
    1. Hage D.S., Austin J. High-performance affinity chromatography and immobilized serum albumin as probes for drug and hormone binding. J. Chromatogr. B Biomed. Sci. Appl. 2000;739:39–54. - PubMed

Publication types